Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
* Investigate the safety and tolerability of multiple DCBCI0901 infusions in patients with advanced solid tumor * Pharmacokinetic parameters will be calculated for DCBCI0901, if data permit. * Anti tumor activity: The efficacy endpoint will be the overall response rate (ORR) defined as the proportion of patients who continuously receive treatment after Cycle 1 with a best overall response of complete response (CR) or partial response (PR).
Epistemonikos ID: 63eeb2abc67d9215a9a6a8ce9d157115fe99a79a
First added on: May 11, 2024